OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 8.5 days from acceptance to publication (median values for papers published in this journal in the first half of 2019, 1-2 days of FREE language polishing time is also included in this period).
Pharmacogenomics in Drug Development
Submission Deadline: November 15, 2020 (Open) Submit Now
Eugenia Yiannakopoulou, MD, MSc, PhD
Academic Teacher, Department of Biomedical Sciences, Faculty of Health Sciences, University of West Attica, Athens, Greece
Research Interests: Pharmacogenomics and drug safety; non steroidal anti-inflammatory agents; prooxidants-antioxidants; systematic review-meta-analysis; breast cancer endocrine treatment; breast cancer targeted therapy; breast cancer chemoprophylaxis
About This Topic
Pharmacogenomics is the study of how genes affect a person’s response to drugs. Its name (pharmaco- + genomics) reflects its combining of pharmacology and genomics. Pharmacogenomics may be applied to several areas of medicine, including pain management, cardiology, oncology, and psychiatry. A place may also exist in forensic pathology, in which pharmacogenomics can be used to determine the cause of death in drug-related deaths where no findings emerge using autopsy. In addition, pharmacogenomics is an important part of precision medicine, as well as one of the most promising parts in the field of precision medicine to realize the clinical routine use of pharmacogenomics and promote the progress of precision medicine.
Pharmacogenomics studies require a multidisciplinary approach because drug targets and adverse effects often involve different organ systems or clinical specialties. They require expertise in many different areas, both preclinical and clinical, including but not limited to pharmacology, genetics, genomics, statistics, bioinformatics, and medicine.
The field of pharmacogenomics is still in its infancy. Its use is currently quite limited, but new approaches are under study in clinical trials. Therefore, in this special issue, we will seek to the articles which reflect the information on current research of pharmacogenomics and drug development. Original research reports, review articles, communications, and perspectives etc. are welcome in all areas pertinent to this topic.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.